[Skip to Navigation]
Views 374
Citations 0
Invited Commentary
July 15, 2021

Patching and Atropine for Severe Amblyopia: Are Both Better Than Patching Alone?

Author Affiliations
  • 1Department of Ophthalmology and Visual Sciences, Medical School, University of Michigan, Ann Arbor
  • 2Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor
  • 3Children’s Eye Care of Michigan, West Bloomfield
  • 4Department of Ophthalmology, Children’s Hospital of Michigan, Detroit
JAMA Ophthalmol. Published online July 15, 2021. doi:10.1001/jamaophthalmol.2021.2425

Guidance on the treatment of amblyopia has benefited substantially from outcomes obtained from randomized clinical trials (RCTs). Most RCTs on amblyopia treatment have been conducted by the National Eye Institute–supported Pediatric Eye Disease Investigator Group (PEDIG). The PEDIG public website1 shows the breadth of amblyopia research reported by that group and provides a key resource not only for guiding amblyopia eye care professionals, but also for instructing the design, conduct, and interpretation of contemporary clinical research on amblyopia treatment.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words